Search results for "Biphenyl Compound"

showing 10 items of 62 documents

Cytotoxicity of the bisphenolic honokiol from Magnolia officinalis against multiple drug-resistant tumor cells as determined by pharmacogenomics and …

2014

A main problem in oncology is the development of drug-resistance. Some plant-derived lignans are established in cancer therapy, e.g. the semisynthetic epipodophyllotoxins etoposide and teniposide. Their activity is, unfortunately, hampered by the ATP-binding cassette (ABC) efflux transporter, P-glycoprotein. Here, we investigated the bisphenolic honokiol derived from Magnolia officinalis. P-glycoprotein-overexpressing CEM/ADR5000 cells were not cross-resistant to honokiol, but MDA-MB-231 BRCP cells transfected with another ABC-transporter, BCRP, revealed 3-fold resistance. Further drug resistance mechanisms analyzed study was the tumor suppressor TP53 and the epidermal growth factor recepto…

HonokiolATP Binding Cassette Transporter Subfamily BPharmaceutical ScienceBiologyPharmacologyLignanschemistry.chemical_compoundGefitinibCell Line TumorDrug DiscoverymedicineATP Binding Cassette Transporter Subfamily G Member 2HumansEpidermal growth factor receptorCytotoxicityPI3K/AKT/mTOR pathwayOligonucleotide Array Sequence AnalysisPharmacologyBiphenyl CompoundsTransfectionbiology.organism_classificationAntineoplastic Agents PhytogenicDrug Resistance MultipleNeoplasm ProteinsErbB ReceptorsMolecular Docking SimulationMagnolia officinalisComplementary and alternative medicinechemistryDrug Resistance NeoplasmMagnoliaPharmacogeneticsbiology.proteinMolecular MedicineATP-Binding Cassette TransportersErlotinibTumor Suppressor Protein p53Transcriptomemedicine.drugSignal TransductionPhytomedicine : international journal of phytotherapy and phytopharmacology
researchProduct

The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.

2001

To determine the antihypertensive efficacy, effect duration and safety of the angiotensin II type 1 receptor blocker candesartan cilexetil and the angiotensin converting enzyme inhibitor enalapril once daily in patients with mild to moderate hypertension.A multicenter, randomised, double-blind parallel group study was performed in Finland, France, the Netherlands, Spain and Sweden. Three-hundred-and-ninety-five men and women in the age range 20-80 years with primary hypertension were randomised to an 8-week double-blind treatment period with either candesartan cilexetil 8-16 mg or enalapril 10-20 mg once daily, with forced dose titration after 4 weeks. Non-invasive ambulatory blood pressure…

AdultMalemedicine.medical_specialtyAmbulatory blood pressureTime Factorsmedicine.medical_treatmentDiastoleTetrazolesAngiotensin-Converting Enzyme InhibitorsBlood PressureAngiotensin Receptor AntagonistsDouble-Blind MethodEnalaprilHeart RateInternal medicineInternal MedicinemedicineHumansProdrugsEnalaprilAntihypertensive AgentsAgedAged 80 and overChemotherapybiologybusiness.industryBiphenyl CompoundsAngiotensin-converting enzymeGeneral MedicineMiddle AgedAngiotensin IICandesartanEndocrinologyTherapeutic EquivalencyACE inhibitorHypertensionbiology.proteinCardiologyBenzimidazolesFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugBlood pressure
researchProduct

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

2015

Background— Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. Methods and Results— We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of med…

Angiotensin receptorVascular damage Radboud Institute for Health Sciences [Radboudumc 16]receptorsTetrazolesheart failureAngiotensin-Converting Enzyme InhibitorsKaplan-Meier EstimateSacubitrilAngiotensin; Heart failure; Neprilysin; Receptors; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Double-Blind Method; Enalapril; Heart Failure; Humans; Kaplan-Meier Estimate; Natriuretic Peptide Brain; Neprilysin; Peptide Fragments; Risk Factors; Stroke Volume; Survivors; Tetrazoles; Treatment Outcome; Troponin; Disease Progression; Medicine (all); Cardiology and Cardiovascular Medicine; Physiology (medical)AngiotensinEnalaprilRisk FactorsEnalapril/therapeutic useNatriuretic Peptide BrainHeart Failure/bloodSurvivorsReceptorNeprilysinAminobutyrates: Systèmes cardiovasculaire & respiratoire [D03] [Sciences de la santé humaine]Troponin/bloodTroponinAngiotensin Receptor Antagonists/therapeutic useDrug CombinationsAngiotensin-Converting Enzyme Inhibitors/therapeutic useTreatment OutcomeTetrazoles/therapeutic useCardiologyDisease ProgressionValsartanNeprilysinHeart Failure/blood/drug therapy/physiopathologyCardiology and Cardiovascular Medicinemedicine.drugReceptormedicine.medical_specialtyHeart failureneprilysinAngiotensin Receptor Antagonistsreceptors angiotensinDouble-Blind MethodPhysiology (medical)Internal medicineRenin–angiotensin systemmedicineHumansheart failure neprilysin receptors angiotensinEnalaprilbusiness.industryBiphenyl CompoundsStroke Volumemedicine.diseasePeptide FragmentsEndocrinologyAminobutyrates/therapeutic useStroke Volume/physiologyHeart failureNatriuretic Peptide Brain/blood: Cardiovascular & respiratory systems [D03] [Human health sciences]businessNeprilysin/antagonists & inhibitorsPeptide Fragments/bloodSacubitril ValsartanBiomarkersBiomarkers/blood
researchProduct

Phytochemical profiles, phototoxic and antioxidant properties of eleven Hypericum species - A comparative study

2018

Hypericum is one out of the nine genera belonging to the botanical family Clusiaceae Lindl (syn. Hypericaceae Juss.; APG III, 2009). The genus contains 484 species spread worldwide, one of which, Hypericum perforatum, is largely used in folk medicine. The aim of this study was to evaluate the chemical composition, along with the antioxidant and phototoxic activity, of 11 Hypericum species grown in Sicily (H. perforatum L., H. aegypticum L., H. androsaemum L., H. calycinum L., H. hircinum L., H. hirsutum L., H. montanum L., H. patulum Thunb., H. perfoliatum L., H. pubescens Boiss., H. tetrapterum Fr.). Samples of flowering tops collected from these Hypericum species were extracted and analys…

0106 biological sciencesDPPHHyperforinAntioxidants Hyperforin Hypericin Hypericum species (Clusiaceae Lindl.) Phototoxicity; PolyphenolsPhytochemicalsHypericinFlowersPlant ScienceHorticultureHypericaceae01 natural sciencesBiochemistryAntioxidantsMass SpectrometryPhototoxicityMicechemistry.chemical_compoundPicratesSpecies SpecificityHypericum species (Clusiaceae Lindl.) Phototoxicity Polyphenols Hypericin Hyperforin AntioxidantsAnimalsHypericum species (Clusiaceae Lindl.)Molecular BiologyChromatography High Pressure LiquidbiologyTraditional medicine010405 organic chemistryChemistryBiphenyl CompoundsPolyphenolsHypericum perforatumGeneral MedicineFibroblastsbiology.organism_classificationSettore AGR/02 - Agronomia E Coltivazioni Erbacee0104 chemical sciencesHypericinHyperforinPhotochemotherapyPhytochemicalPolyphenolNIH 3T3 CellsAntioxidantReactive Oxygen SpeciesHypericumHypericumDermatitis Phototoxic010606 plant biology & botany
researchProduct

Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis.

2008

The chimeric monoclonal antibody rituximab is the standard of care for patients with B-cell non-Hodgkin lymphoma (B-NHL). Rituximab mediates complementdependent cytotoxicity and antibodydependent cellular cytotoxicity of CD20-positive human B cells. In addition, rituximab sensitizes B-NHL cells to cytotoxic chemotherapy and has direct apoptotic and antiproliferative effects. Whereas expression of the CD20 antigen is a natural prerequisite for rituximab sensitivity, cell-autonomous factors determining the response of B-NHL to rituximab are less defined. To this end, we have studied rituximab-induced apoptosis in human B-NHL models. We find that rituximab directly triggers apoptosis via the m…

Programmed cell deathLymphoma B-CellImmunologyMedizinAntineoplastic AgentsApoptosisMice SCIDBiochemistryPiperazinesNitrophenolsAntibodies Monoclonal Murine-DerivedMicePhosphatidylinositol 3-Kinasesimmune system diseaseshemic and lymphatic diseasesCell Line TumormedicineAnimalsHumansB-cell lymphomaCD20SulfonamidesbiologyBcl-2 familyBiphenyl CompoundsAntibodies MonoclonalCell BiologyHematologymedicine.diseaseAntigens CD20LymphomaGene Expression Regulation NeoplasticProto-Oncogene Proteins c-bcl-2Apoptosisbiology.proteinCancer researchMyeloid Cell Leukemia Sequence 1 ProteinRituximabSignal transductionRituximabNeoplasm Transplantationmedicine.drugSignal TransductionBlood
researchProduct

Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer

2014

Lung cancer is the most common cause of cancer-related mortality worldwide, urging the discovery of novel molecular targets and therapeutic strategies. Stem cells have been recently isolated from non-small cell lung cancer (NSCLC), thus allowing the investigation of molecular pathways specifically active in the tumorigenic population. We have found that Bcl-XL is constantly expressed by lung cancer stem cells (LCSCs) and has a prominent role in regulating LCSC survival. Whereas chemotherapeutic agents were scarcely effective against LCSC, the small molecule Bcl-2/Bcl-XL inhibitor ABT-737, but not the selective Bcl-2 inhibitor ABT-199, induced LCSC death at nanomolar concentrations. Differen…

Lung NeoplasmsMice SCIDPharmacologyPiperazinesAntineoplastic AgentNitrophenolsMiceMice Inbred NODCarcinoma Non-Small-Cell LungCytotoxic T cellNon-Small-Cell Lungeducation.field_of_studySulfonamidesTumorAnimals; Antineoplastic Agents; Biphenyl Compounds; Carcinoma Non-Small-Cell Lung; Cell Line Tumor; Cell Proliferation; Cell Survival; Female; Humans; Lung Neoplasms; Mice Inbred NOD; Mice SCID; Neoplastic Stem Cells; Nitrophenols; Piperazines; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays; bcl-X Protein; Molecular Biology; Cell BiologyTumor BurdenAnimals; Antineoplastic Agents; Biphenyl Compounds; Carcinoma Non-Small-Cell Lung; Cell Line Tumor; Cell Proliferation; Cell Survival; Female; Humans; Lung Neoplasms; Mice Inbred NOD; Mice SCID; Neoplastic Stem Cells; Nitrophenols; Piperazines; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays; bcl-X ProteinNeoplastic Stem CellsFemaleStem cellHumanmedicine.drugXenograft Model Antitumor AssayCell SurvivalPopulationbcl-X ProteinAntineoplastic AgentsBiologySCIDSulfonamideCell LineCancer stem cellCell Line TumormedicineAnimalsHumanseducationLung cancerPiperazineMolecular BiologyCell ProliferationSettore MED/04 - Patologia GeneraleOriginal PaperNitrophenolAnimalCell growthCarcinomaBiphenyl CompoundsCell Biologymedicine.diseaseXenograft Model Antitumor AssaysGemcitabineLung NeoplasmCell cultureBiphenyl CompoundCancer researchInbred NODNeoplastic Stem Cell
researchProduct

Curcumin at Low Doses Potentiates and at High Doses Inhibits ABT-737-Induced Platelet Apoptosis

2021

Curcumin is a natural bioactive component derived from the turmeric plant Curcuma longa, which exhibits a range of beneficial activities on human cells. Previously, an inhibitory effect of curcumin on platelets was demonstrated. However, it is unknown whether this inhibitory effect is due to platelet apoptosis or procoagulant platelet formation. In this study, curcumin did not activate caspase 3-dependent apoptosis of human platelets, but rather induced the formation of procoagulant platelets. Interestingly, curcumin at low concentration (5 µM) potentiated, and at high concentration (50 µM) inhibited ABT-737-induced platelet apoptosis, which was accompanied by inhibition of ABT-737-mediated…

0301 basic medicinePharmacologyPiperazinesNitrophenolschemistry.chemical_compound0302 clinical medicinePlateletBiology (General)SpectroscopyCaspaseSulfonamidesbiologyKinaseapoptosisGeneral MedicinethrombinDrug Resistance Multipleprocoagulant activityComputer Science ApplicationsChemistry030220 oncology & carcinogenesisplateletsmedicine.drugBlood PlateletsAdenosine monophosphateautophagyCurcuminQH301-705.5ArticleCatalysisInorganic Chemistry03 medical and health sciencesCurcumaThrombinmedicineHumansATP Binding Cassette Transporter Subfamily B Member 1Physical and Theoretical ChemistryQD1-999Molecular BiologyProtein kinase BPlant ExtractsBiphenyl CompoundsOrganic ChemistryAdenosine Monophosphate030104 developmental biologychemistryApoptosisbiology.proteinCurcuminProto-Oncogene Proteins c-aktPlatelet Aggregation InhibitorsInternational Journal of Molecular Sciences
researchProduct

Antioxidant and neuroprotective effects of synthesized sintenin derivatives

2009

Three series of sintenin derivatives (compounds 1-14) were designed and prepared and their antioxidative and neuroprotective effects were evaluated. The in vitro models of scavenging 1,1-diphenyl-2-picrylhydrazyl (DPPH) radicals, chelating ferrous ions, inhibiting the rat brain homogenates lipid peroxidation, and protecting neurons damaged by hydrogen peroxide were employed for bioassays. It was found that sintenin derivatives 4 and 13 showed remarkable antioxidative and neuroprotective activities.

AntioxidantDPPHmedicine.medical_treatmentRadicalNeuroprotectionAntioxidantsRats Sprague-DawleyLipid peroxidationchemistry.chemical_compoundPicratesDrug DiscoverymedicineAnimalsChelationHydrogen peroxideCells CulturedChelating AgentsNeuronsPharmacologyChemistryBiphenyl CompoundsHydrogen PeroxideGeneral MedicineRatsBiphenyl compoundNeuroprotective AgentsBiochemistryLipid PeroxidationPropionatesJournal of Enzyme Inhibition and Medicinal Chemistry
researchProduct

Biphenyl and fluorinated derivatives: liver enzyme-mediated mutagenicity detected in Salmonella typhimurium and Chinese hamster V79 cells.

1992

Abstract Hepatocarcinogenic polychlorinated and polybrominated biphenyls usually show negative results in in vitro mutagenicity assays. Problems in their testing result from their low water solubility and their slow rate of metabolism. We therefore investigated better soluble model compounds, namely biphenyl and its 3 possible monofiuorinated derivatives. In the direct test, these compounds proved tobe nonmutagenic in Salmonella typhimurium TA98 and TA100 (reversion to histidine prototrophy) and in Chinese hamster V79 cells (acquisition of resistance to 6-thioguanine). However, when the exposure was carried out in the presence of NADPH-fortified postmitochondrial fraction of liver homogenat…

MaleSalmonella typhimuriumendocrine systemChinese hamsterAmes testCell LineToxicologychemistry.chemical_compoundStructure-Activity RelationshipCricetulusCricetinaeAnimalsBiotransformationBiphenylbiologyChemistryMutagenicity TestsBiphenyl CompoundsRats Inbred StrainsGeneral MedicineMetabolismbiology.organism_classificationEnterobacteriaceaeIn vitroRatsBiochemistryMicrosomal epoxide hydrolaseMicrosomes LiverPolybrominated BiphenylsMutation research
researchProduct

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?

2021

BackgroundCirculating Neprilysin (sNEP) has emerged as a potential prognostic biomarker in heart failure (HF). In PARAGON-HF benefit of sacubitril/valsartan was only observed in patients with left ventricular ejection fraction (LVEF) ≤57%. We aimed to assess the prognostic value of sNEP in outpatients with HF and LVEF >57%, in comparison with patients with LVEF ≤57%.MethodsConsecutive HF outpatients were included from May-2006 to February-2016. The primary endpoint was the composite of all-cause death or HF hospitalization and the main secondary endpoint was the composite of cardiovascular death or HF hospitalization. For the later competing risk methods were used.ResultssNEP was measure…

MalePhysiologyCancer TreatmentCardiovascular MedicineBiochemistrySacubitrilMedical ConditionsClinical endpointMedicine and Health SciencesMultidisciplinaryEjection fractionPharmaceuticsAminobutyratesHazard ratioQRMiddle AgedPrognosisBody FluidsCardiovascular TherapyBloodValsartanOncologyCardiovascular DiseasesCardiologycardiovascular systemMedicineValsartanFemaleNeprilysinAnatomymedicine.drugcirculatory and respiratory physiologyResearch Articlemedicine.medical_specialtyScienceCardiologyDrug TherapyInternal medicinemedicineHumanscardiovascular diseasesAgedProportional Hazards ModelsHeart FailureProportional hazards modelbusiness.industryBiphenyl CompoundsBiology and Life SciencesStroke VolumeCardiovascular Disease Riskmedicine.diseaseHeart failurebusinessSacubitril ValsartanBiomarkersReceptor Antagonist TherapyEjection FractionPloS one
researchProduct